Enteropathy-Associated T-Cell Lymphoma EATL

EATL is a rare and aggressive cancer of T-lymphocytes that arises in the lining of the small intestine, almost exclusively in patients with long-standing or unrecognised celiac disease. The lymphoma develops from intraepithelial T-lymphocytes that have been chronically stimulated by gluten-driven inflammation. It is one of the most serious complications of celiac disease and carries a poor prognosis, though treatment is improving with multimodal approaches including stem cell transplantation.

Yes. Long-standing or inadequately treated celiac disease is a well-established risk factor for EATL. Persistent gluten exposure drives chronic intestinal mucosal inflammation, which over time can lead to clonal expansion of abnormal intraepithelial T-lymphocytes (a condition called Refractory Celiac Disease Type II or RCD-II), which in turn can transform into frank EATL. Maintaining a strict lifelong gluten-free diet substantially reduces but does not entirely eliminate this risk.

EATL (classic) is strongly associated with celiac disease and HLA-DQ2/DQ8; it has large pleomorphic lymphocytes and is CD56-negative. MEITL (Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma) is not associated with celiac disease, occurs more commonly in Asian populations, has a distinct immunophenotype (CD8+, CD56+), and is associated with JAK1/STAT3 mutations. They are distinct WHO 2022 entities requiring different diagnostic approaches and potentially different treatments. Expert haematopathological review is essential for correct classification.

EATL tumour cells destroy the intestinal wall, creating areas of necrosis that are prone to perforation. Intestinal perforation, obstruction, and haemorrhage are common presenting events in EATL, often requiring emergency laparotomy. In many patients, EATL is first suspected or diagnosed when a surgical specimen is sent to pathology after an emergency bowel resection. This is why any patient with celiac disease presenting with acute abdominal symptoms must be urgently evaluated.

The two most commonly used induction regimens are CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and the IVE-MTX protocol (ifosfamide, vincristine, etoposide alternating with high-dose methotrexate). IVE-MTX has shown better outcomes than CHOP in some series. Treatment is very challenging due to malnutrition, bowel complications, and poor tolerance; dose reductions and supportive care are often required. Standard chemotherapy is generally followed by stem cell transplantation in eligible patients.

ASCT consolidation — using the patient's own stem cells to support recovery from high-dose chemotherapy — is recommended for EATL patients who achieve complete remission after induction and who are physically fit enough to tolerate the procedure. ASCT is associated with the best long-term outcomes in EATL. Unfortunately, many patients cannot proceed to ASCT due to poor performance status, malnutrition, post-surgical complications, or failure to achieve remission. Specialist haematology assessment determines eligibility.

Yes. Several novel approaches are in clinical investigation. JAK1/STAT3 pathway inhibitors (ruxolitinib) are being evaluated given that JAK/STAT mutations are found in some EATL cases. Epigenetic therapies targeting SETD2 loss — the most common molecular defect in EATL — are under investigation. Brentuximab vedotin (anti-CD30) is being explored in CD30-expressing EATL. Checkpoint inhibitors (anti-PD-1) are in trials for peripheral T-cell lymphomas broadly. CancerFax can help identify the most appropriate clinical trial for your specific molecular profile.

Yes. CancerFax assists EATL patients and families with biopsy and molecular profiling report review, second opinion coordination with international T-cell lymphoma specialists, eligibility assessment for ASCT programmes, and access to clinical trials for JAK inhibitors, epigenetic therapies, and novel approaches — including programmes in India, China, Europe, and the US. Given the rarity and severity of EATL, connecting with the right specialist centre early is critical, and our team works to facilitate that pathway as efficiently as possible.